Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome.

Published

Journal Article

The Kasabach Merritt syndrome consists of thrombocytopenia, microangiopathic hemolytic anemia, and a localized consumption coagulopathy that develops within the abnormal vascular channels of a hemangioma. In general, these patients demonstrate only mild abnormalities of screening clotting tests, but they can potentially develop life-threatening complications. We present a patient who developed a severe anemia that was refractory to erythrocyte transfusions. Treatment with epsilon-aminocaproic acid to inhibit fibrinolysis and cryoprecipitate to replenish his deficient circulating fibrinogen interrupted the cycle of his systemic coagulopathy and enabled us to transfuse him to a normal hematocrit.

Full Text

Duke Authors

Cited Authors

  • Ortel, TL; Onorato, JJ; Bedrosian, CL; Kaufman, RE

Published Date

  • September 1988

Published In

Volume / Issue

  • 29 / 1

Start / End Page

  • 44 - 48

PubMed ID

  • 3177369

Pubmed Central ID

  • 3177369

Electronic International Standard Serial Number (EISSN)

  • 1096-8652

International Standard Serial Number (ISSN)

  • 0361-8609

Digital Object Identifier (DOI)

  • 10.1002/ajh.2830290111

Language

  • eng